|
|
|
Corporate Profile: Oncolytics
Biotech
| Summary: |
|
Oncolytics Biotech is involved primarily in the
development of the reovirus for the treatment
of cancer. Reovirus has been shown to preferentially
replicate in cells with an activated Ras pathway.
|
| Address (HQ): |
1167 Kensington Crescent NW
Suite 210
Calgary, AB T2N 1X7
Canada |
| Phone #'s (HQ): |
Main |
(403) 670-7377 |
| Human Resources |
not known |
| Investor Relations |
not known |
| Fax #'s (HQ): |
Main |
(403) 283-0858 |
| Human Resources |
not known |
| Investor Relations |
not known |
| Financial
information: |
| ONCY |
| Number
of employees: |
| not
known |
| Issued United States patents: |
Issued U.S. patents: 1976-present: patent
link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
